Back

Early developmental placental defects and pregnancy loss in lupus mice expressing human TLR8

Davidson, A.; Maria, N.; Xia, Y.; Raparia, C.; Lin, K.; Martinez, S.; Yi, Z.; Zhang, W.; Aziz, M.; Wang, P.; Guerra, M.; Salmon, J.; Sones, J. L.; Arazi, A.; Hoover, P.

2026-02-09 immunology
10.64898/2026.02.07.701591 bioRxiv
Show abstract

Anti-phospholipid (APL) autoantibodies confer a high risk for adverse pregnancy outcomes, especially in Systemic Lupus Erythematosus (SLE). While human TLR8 (huTLR8) has been implicated in APL antibody-mediated placental injury in vitro, its in vivo role in pregnancy is unexplored. We report a novel mouse model of pregnancy loss in SLE-prone mice expressing huTLR8. Placental analysis revealed early developmental defects starting post-implantation, including a thin junctional zone, impaired vascularization, infarcts, and inflammation. Profound immune dysregulation was evident at E8.5 including increased myeloid cells and CD8 T cells and decreased uterine natural killer (uNK) cells. RNA sequencing revealed downregulated pregnancy-specific glycoproteins, reduced uNK cell-associated genes, and an upregulated myeloid cell signature. Bone marrow chimera studies demonstrated preferential activation of huTLR8-expressing placental Ly6C+ monocytes. Spatial transcriptomics at E9.5 confirmed uNK cell loss, decreased IL15 expression by both stromal and myeloid cells, and discrete inflammatory aggregates in the maternal layers containing myeloid cells and IFN{gamma}-expressing CD8 T cells. We propose that huTLR8, likely through myeloid cell activation and cytolytic T cell recruitment, drives placental injury in the context of SLE and APL autoantibodies. This model provides a valuable platform to dissect early pathogenic events in APL-associated pregnancy loss and identify new therapeutic targets.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
JCI Insight
241 papers in training set
Top 0.1%
19.6%
2
Arthritis & Rheumatology
33 papers in training set
Top 0.1%
6.4%
3
Journal of Experimental Medicine
106 papers in training set
Top 0.3%
6.4%
4
Journal of Clinical Investigation
164 papers in training set
Top 0.5%
4.9%
5
Science Translational Medicine
111 papers in training set
Top 0.8%
3.6%
6
Blood
67 papers in training set
Top 0.5%
3.6%
7
Rheumatology
21 papers in training set
Top 0.2%
3.6%
8
The Journal of Immunology
146 papers in training set
Top 0.5%
3.3%
50% of probability mass above
9
Cell Reports Medicine
140 papers in training set
Top 2%
3.1%
10
Nature Communications
4913 papers in training set
Top 42%
3.1%
11
Cell Reports
1338 papers in training set
Top 20%
2.1%
12
eLife
5422 papers in training set
Top 38%
1.9%
13
Annals of the Rheumatic Diseases
32 papers in training set
Top 0.4%
1.9%
14
Blood Advances
54 papers in training set
Top 0.6%
1.9%
15
Leukemia
39 papers in training set
Top 0.5%
1.5%
16
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 35%
1.5%
17
Frontiers in Immunology
586 papers in training set
Top 5%
1.3%
18
iScience
1063 papers in training set
Top 21%
1.2%
19
Clinical Immunology
21 papers in training set
Top 0.4%
1.1%
20
EMBO Molecular Medicine
85 papers in training set
Top 3%
1.1%
21
Scientific Reports
3102 papers in training set
Top 69%
1.0%
22
Journal of the Pediatric Infectious Diseases Society
10 papers in training set
Top 0.1%
0.9%
23
Circulation
66 papers in training set
Top 2%
0.9%
24
Immunology
29 papers in training set
Top 0.8%
0.9%
25
Haematologica
24 papers in training set
Top 0.4%
0.8%
26
Science Immunology
81 papers in training set
Top 2%
0.8%
27
Clinical & Translational Immunology
22 papers in training set
Top 0.3%
0.7%
28
Disease Models & Mechanisms
119 papers in training set
Top 3%
0.7%
29
Circulation Research
39 papers in training set
Top 1%
0.6%
30
The Journal of Infectious Diseases
182 papers in training set
Top 6%
0.6%